Limits...
Retrospective public health impact of a quadrivalent influenza vaccine in the United States.

Crépey P, de Boer PT, Postma MJ, Pitman R - Influenza Other Respir Viruses (2015)

Bottom Line: Elderly (≥65 years) and young seniors (50-64 years) benefit most from QIV, with 21% and 18% reductions in B lineage cases.Reducing cross-protection to 50%, 30%, and 0% of the VE of the matched vaccine improves the relative benefit of QIV to 25%, 30%, and 34% less B lineage cases.Using a dynamic retrospective framework with real-life vaccine mismatch, our analysis shows that QIV routine vaccination in the United States has the potential to substantially reduce the number of influenza infections, even with relatively high estimates of TIV-induced cross-protection.

View Article: PubMed Central - PubMed

Affiliation: EHESP Rennes, Sorbonne Paris-cité, Paris, France.

No MeSH data available.


Related in: MedlinePlus

Cross-protection sensitivity analysis showing reduction in B cases with quadrivalent influenza vaccine (QIV) compared with trivalent influenza vaccine (TIV) over the period 2000–2013. The vertical line shows the base case scenario.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4549101&req=5

fig04: Cross-protection sensitivity analysis showing reduction in B cases with quadrivalent influenza vaccine (QIV) compared with trivalent influenza vaccine (TIV) over the period 2000–2013. The vertical line shows the base case scenario.

Mentions: Assuming a cross-protection of 70% of the VE of a matching vaccine, the model predicts that QIV would have prevented on average 15·80% (10·37%; 22·7%) (min–max, moving average over 5 years) extra B lineage cases than TIV over the period 2000–2013. Figure3 and Table3 illustrate the multiyear incidence evolution of B/Victoria and B/Yamagata epidemics under TIV and QIV scenarios. The first point to notice is the relatively large variations in cases prevented by QIV, years with a mismatched TIV vaccine being mainly years with the highest impact of QIV. It appears that over the period 2000–2013, QIV would have prevented a cumulative number of more than 6·2 million cases. Two other situations can be highlighted. First, several years show a cocirculation of the two lineages, which allows QIV to be beneficial even during ‘vaccine match’ years. Second, with a QIV scenario, some years display a slightly higher incidence for one B lineage than a scenario with TIV alone. As shown in Table3, these correspond to years with TIV matching the circulating B lineage (2006–2007, 2009–2011), and more importantly, they follow a string of years combining TIV mismatch and medium to high B circulation, leading to large numbers of cases prevented by QIV (>1·6 million in 2004–2006 and >2·7 million in 2007–2009). Concerning elderly individuals (age ≥65 years) and young seniors (age 50–64 years), Figure4 shows that they benefit the most from QIV, with 21% and 18% reduction in B cases, respectively. Of note, the infant population (age 0–6 months), not (yet) vaccinated, benefits from QIV thanks to indirect protection of the other age groups.


Retrospective public health impact of a quadrivalent influenza vaccine in the United States.

Crépey P, de Boer PT, Postma MJ, Pitman R - Influenza Other Respir Viruses (2015)

Cross-protection sensitivity analysis showing reduction in B cases with quadrivalent influenza vaccine (QIV) compared with trivalent influenza vaccine (TIV) over the period 2000–2013. The vertical line shows the base case scenario.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4549101&req=5

fig04: Cross-protection sensitivity analysis showing reduction in B cases with quadrivalent influenza vaccine (QIV) compared with trivalent influenza vaccine (TIV) over the period 2000–2013. The vertical line shows the base case scenario.
Mentions: Assuming a cross-protection of 70% of the VE of a matching vaccine, the model predicts that QIV would have prevented on average 15·80% (10·37%; 22·7%) (min–max, moving average over 5 years) extra B lineage cases than TIV over the period 2000–2013. Figure3 and Table3 illustrate the multiyear incidence evolution of B/Victoria and B/Yamagata epidemics under TIV and QIV scenarios. The first point to notice is the relatively large variations in cases prevented by QIV, years with a mismatched TIV vaccine being mainly years with the highest impact of QIV. It appears that over the period 2000–2013, QIV would have prevented a cumulative number of more than 6·2 million cases. Two other situations can be highlighted. First, several years show a cocirculation of the two lineages, which allows QIV to be beneficial even during ‘vaccine match’ years. Second, with a QIV scenario, some years display a slightly higher incidence for one B lineage than a scenario with TIV alone. As shown in Table3, these correspond to years with TIV matching the circulating B lineage (2006–2007, 2009–2011), and more importantly, they follow a string of years combining TIV mismatch and medium to high B circulation, leading to large numbers of cases prevented by QIV (>1·6 million in 2004–2006 and >2·7 million in 2007–2009). Concerning elderly individuals (age ≥65 years) and young seniors (age 50–64 years), Figure4 shows that they benefit the most from QIV, with 21% and 18% reduction in B cases, respectively. Of note, the infant population (age 0–6 months), not (yet) vaccinated, benefits from QIV thanks to indirect protection of the other age groups.

Bottom Line: Elderly (≥65 years) and young seniors (50-64 years) benefit most from QIV, with 21% and 18% reductions in B lineage cases.Reducing cross-protection to 50%, 30%, and 0% of the VE of the matched vaccine improves the relative benefit of QIV to 25%, 30%, and 34% less B lineage cases.Using a dynamic retrospective framework with real-life vaccine mismatch, our analysis shows that QIV routine vaccination in the United States has the potential to substantially reduce the number of influenza infections, even with relatively high estimates of TIV-induced cross-protection.

View Article: PubMed Central - PubMed

Affiliation: EHESP Rennes, Sorbonne Paris-cité, Paris, France.

No MeSH data available.


Related in: MedlinePlus